Stock Rating Report for VRML

Ticker: 

Stock Information

Ticker VRML
Company Name Vermillion, Inc
Current Price $1.31
Previous Close $1.31
Industry Diagnostic Substances
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for VRML. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Vermillion, Inc next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and women's health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the OVA1 Test'), which addresses pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine- The University of Texas M.D. Anderson Cancer Center- University College London- The University of Texas Medical Branch- The Katholieke Universiteit Leuven- Clinic of Gynecology and Clinic of Oncology, Rigshospitalet- Copenhagen University Hospital- The Ohio State University Research Foundation- Stanford University- and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests. Vermillion, Inc. serves clinical reference laboratories, hospital laboratories, and physician offices. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.


Latest News

Wed, 22 Feb 2012 11:39:33 GMTVermillion, Inc. Earnings Call scheduled for Thu, Feb 23
Fri, 17 Feb 2012 18:04:26 GMTVERMILLION, INC. Financials
Tue, 14 Feb 2012 11:15:50 GMTVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
Mon, 06 Feb 2012 20:00:00 GMTVermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
Fri, 03 Feb 2012 06:11:08 GMTNasdaq ?Threshold? Securities for Feb. 2
Thu, 02 Feb 2012 05:21:09 GMTNasdaq ?Threshold? Securities for Feb. 1
Wed, 01 Feb 2012 04:55:04 GMTNasdaq ?Threshold? Securities for Jan. 31
Tue, 31 Jan 2012 05:05:00 GMTNasdaq ?Threshold? Securities for Jan. 30
Thu, 12 Jan 2012 01:00:13 GMTLargest Nasdaq Short Interest Percent Decreases as of Dec. 30
Thu, 05 Jan 2012 11:01:41 GMTVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Byl
Wed, 04 Jan 2012 13:00:00 GMTVermillion Sharpens Focus and Streamlines Operations in 2012
Mon, 02 Jan 2012 10:21:14 GMTVermillion Hijacked
Thu, 22 Dec 2011 15:18:25 GMTVERMILLION, INC. Files SEC form 8-K, Other Events
Tue, 20 Dec 2011 22:16:30 GMTVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements a
Tue, 20 Dec 2011 12:58:36 GMTVermillion: Turning The Page Over
Mon, 19 Dec 2011 13:00:00 GMTVermillion Completes the Acquisition of Correlogic Systems' Ovarian Cancer Diagnostics Business
Wed, 16 Nov 2011 17:36:22 GMT7 Stocks Under $10 Moving Higher
Mon, 14 Nov 2011 22:12:43 GMTVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mon, 14 Nov 2011 22:12:43 GMTVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Wed, 09 Nov 2011 13:30:00 GMTVermillion Inc Earnings & Co. Update Call scheduled for 8:30 am ET today
News provided by Yahoo! Finance